Sickle Cell Disease (SCD) Bone Pain Study
Primary Purpose
Sickle Cell Disease, Sickle Cell Anemia, Low Bone Density
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dual-energy X-ray absorptiometry
Vertebral fracture analysis
Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire
Sponsored by
About this trial
This is an interventional diagnostic trial for Sickle Cell Disease focused on measuring sickle cell disease, sickle cell anemia, low bone density, osteoporosis, osteopenia, low bone mass
Eligibility Criteria
Inclusion Criteria:
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written informed consent
- Ability to lay on a DXA scanner
- Negative urine pregnancy test for women of childbearing potential at study entry
Exclusion Criteria:
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (any cause) within 2 weeks of study entry
Sites / Locations
- UC Davis Comprehensive Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
SCD Bone Pain Study Cohort
Arm Description
Prospective cohort of 50 adults with sickle cell disease (SCD) undergoing research DXA scan to assess bone mineral density and thoracolumbar morphometry for vertebral fracture analysis
Outcomes
Primary Outcome Measures
Bone mineral density Z-scores of lumbar spine, hip, forearm, and whole body
Bone mineral density (g/cm2) and standard deviation from reference mean
Vertebral fracture analysis
Qualitative measure of thoracolumbar vertebral compression fractures
Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) pain scores
Patient-reported outcome measure of pain level in the past 7 days. The ASCQ-Me pain scale ranges from 0-100, with a standardized sickle cell disease population mean of 50 (standard deviation=10), where lower scores signify worse disease impact.
Secondary Outcome Measures
Serum CTX-1
Measurement of C-terminal telopeptide of type I collagen (CTX) in serum
Serum P1NP
Measurement of Procollagen type I N-terminal propeptide (P1NP) in serum
Full Information
NCT ID
NCT05283148
First Posted
March 7, 2022
Last Updated
September 8, 2023
Sponsor
University of California, Davis
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Doris Duke Charitable Foundation
1. Study Identification
Unique Protocol Identification Number
NCT05283148
Brief Title
Sickle Cell Disease (SCD) Bone Pain Study
Official Title
Association Between Low Bone Density, Vertebral Fractures, and Pain in Sickle Cell Disease
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 3, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Doris Duke Charitable Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A prospective study to determine how low bone mineral density and/or vertebral compression fractures associate with pain in adults with sickle cell disease
Detailed Description
The investigators hypothesize that adults with sickle cell disease (SCD) and low bone density and/or vertebral compression fractures on a dual X-ray absorptiometry (DXA) scan (adjusted for age, sex, SCD genotype, relevant labs, presence of osteonecrosis, and SCD-modifying therapies) will report more severe pain than those with normal bone density or no vertebral fractures. The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) is a validated patient-reported outcome measure of physical, mental, and social health in adults with SCD. This cross-sectional observational study involves obtaining a baseline DXA scan, vertebral fracture analysis (VFA) and pain assessment using ASCQ-Me pain impact scores. The investigators plan to recruit 50 adults with SCD followed at University of California Davis Medical Center between Nov 2022- Oct 2023, and anticipate enrolling 4-6 adults with SCD per month. The study endpoints are listed below:
To determine the association between bone density Z-scores and ASCQ-Me pain impact scores in a prospective cohort of adults with SCD
To study the association between Spine Deformity Index scores (SDI, a proxy for vertebral fracture analysis) and ASCQ-Me pain impact scores in a prospective cohort of adults with SCD
To assess the correlation between baseline hematological and biochemical laboratory parameters (including bone biomarkers), bone density, and/or vertebral fractures in a prospective cohort of adults with SCD
The investigators' goal is to complete primary data analysis by Mar 2024. As an exploratory endpoint, 1cc of serum and 5cc of urine will be collected from each study participant once (at baseline), after an overnight fast, for bone biomarker analyses.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease, Sickle Cell Anemia, Low Bone Density, Osteoporosis, Osteopenia, Vertebral Fracture, Vertebral Compression, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
Keywords
sickle cell disease, sickle cell anemia, low bone density, osteoporosis, osteopenia, low bone mass
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective cohort study
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SCD Bone Pain Study Cohort
Arm Type
Other
Arm Description
Prospective cohort of 50 adults with sickle cell disease (SCD) undergoing research DXA scan to assess bone mineral density and thoracolumbar morphometry for vertebral fracture analysis
Intervention Type
Other
Intervention Name(s)
Dual-energy X-ray absorptiometry
Other Intervention Name(s)
DXA scan
Intervention Description
Measure bone mineral density at the lumbar spine, left total hip, left forearm, and whole body
Intervention Type
Other
Intervention Name(s)
Vertebral fracture analysis
Other Intervention Name(s)
VFA
Intervention Description
Obtain thoracolumbar morphometry in DXA scan, then determine presence and severity of vertebral compression fractures by VFA
Intervention Type
Other
Intervention Name(s)
Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire
Other Intervention Name(s)
ASCQ-Me Pain scores
Intervention Description
Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
Primary Outcome Measure Information:
Title
Bone mineral density Z-scores of lumbar spine, hip, forearm, and whole body
Description
Bone mineral density (g/cm2) and standard deviation from reference mean
Time Frame
At enrollment
Title
Vertebral fracture analysis
Description
Qualitative measure of thoracolumbar vertebral compression fractures
Time Frame
At enrollment
Title
Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) pain scores
Description
Patient-reported outcome measure of pain level in the past 7 days. The ASCQ-Me pain scale ranges from 0-100, with a standardized sickle cell disease population mean of 50 (standard deviation=10), where lower scores signify worse disease impact.
Time Frame
At enrollment
Secondary Outcome Measure Information:
Title
Serum CTX-1
Description
Measurement of C-terminal telopeptide of type I collagen (CTX) in serum
Time Frame
Within 18 months after final enrollment
Title
Serum P1NP
Description
Measurement of Procollagen type I N-terminal propeptide (P1NP) in serum
Time Frame
Within 18 months after final enrollment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
Ability to provide written informed consent
Ability to lay on a DXA scanner
Negative urine pregnancy test for women of childbearing potential at study entry
Exclusion Criteria:
Pregnant women
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Prisoners
Hospitalizations (any cause) within 2 weeks of study entry
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Oyebimpe O Adesina, MD, MS
Phone
(916) 703-5166
Email
adesina@ucdavis.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Leyla Y Teos, PhD
Phone
(916) 460-2749
Email
lyteos@ucdavis.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oyebimpe O Adesina, MD, MS
Organizational Affiliation
UC Davis School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
UC Davis Comprehensive Cancer Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leyla Y Teos, PhD
Phone
916-460-2749
Email
lyteos@ucdavis.edu
First Name & Middle Initial & Last Name & Degree
Oyebimpe O Adesina, MD, MS
Phone
(916) 703-5166
Email
adesina@ucdavis.edu
First Name & Middle Initial & Last Name & Degree
Oyebimpe O Adesina, MD, MS
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sickle Cell Disease (SCD) Bone Pain Study
We'll reach out to this number within 24 hrs